BrainPalmSeq: A curated RNA-seq database of palmitoylating and de-palmitoylating enzyme
expression in the mouse brain

Authors: Wild, AR[1]; Hogg, PW[1]; Flibotte, S[2]; Nasseri, G[1]; Hollman, R[1]; Haas, K[1] and Bamji, SX[1]

Affiliations:

1 Department of Cellular and Physiological Sciences, Life Sciences Institute and Djavad Mowafaghian
Centre for Brain Health, University of British Columbia

2 Life Sciences Institute Bioinformatics Facility, University of British Columbia

Correspondence:

Shernaz Bamji, Ph.D.

Department of Cellular and Physiological Sciences

Life Sciences Institute,

Djavad Mowafaghian Centre for Brain Health

University of British Columbia

2350 Health Sciences Mall

Vancouver, B.C., V6T 1Z3

Off: 604-822-4746

Abstract

Protein *S*-palmitoylation is a reversible post-translational lipid modification that plays a critical role in neuronal development and plasticity, while dysregulated *S*-palmitoylation underlies a number of severe neurological disorders. Dynamic *S*-palmitoylation is regulated by a large family of ZDHHC palmitoylating enzymes, their accessory proteins, and a small number of known de-palmitoylating enzymes. Here, we curated and analyzed expression data for the proteins that mediate *S*-palmitoylation from publicly available RNAseq datasets, providing a comprehensive overview of their distribution in the mouse nervous system. We developed a web-tool that enables interactive visualization of the expression patterns for these proteins in the nervous system (http://brainpalmseq.med.ubc.ca/), and explored this resource to find region and cell-type specific expression patterns that give insight into the function of palmitoylating and de-palmitoylating enzymes in the brain and neurological disorders. We found coordinated expression of ZDHHC enzymes with their accessory proteins, de-palmitoylating enzymes and other brain-expressed genes that included an enrichment of *S*-palmitoylation substrates. Finally, we utilized ZDHHC expression patterns to predict and validate palmitoylating enzyme-substrate interactions.

Introduction

Protein *S*-palmitoylation is a post-translational lipid modification that mediates dynamic changes in protein stability, function, and membrane localization. *S*-palmitoylation is defined as the reversible formation of a cysteine residue thioester bond with the fatty acid palmitate, and is the most prevalent post-translational lipid modification in the brain. Dynamic changes in *S*-palmitoylation are critical for neuronal development and synaptic plasticity (Fukata et al., 2013; Fukata and Fukata, 2010; Globa and Bamji, 2017; Matt et al., 2019), oligodendrocyte differentiation and myelination (Ma et al., 2021; Schneider et al., 2005), and astrocyte proliferation (Yuan et al., 2021). Furthermore, numerous neurological and psychiatric diseases have now been attributed to mutations in the genes encoding palmitoylating and de-palmitoylating enzymes, including schizophrenia, intellectual disability and CLN1 disease (Mukai et al., 2004; Nita et al., 2016; Raymond et al., 2007), underscoring the importance of proper regulation of *S*-palmitoylation for normal brain function.

S-Palmitoylation is mediated by a family of ZDHHC enzymes that share a consensus 'Asp-His-His-Cys' catalytic domain. These enzymes are structurally heterogeneous multi-pass transmembrane proteins that localize to a variety of intracellular compartments, including the Golgi apparatus, endoplasmic reticulum (ER), recycling endosomes and the plasma membrane (Globa and Bamji, 2017). The ZDHHC enzymes are known to associate with accessory proteins that regulate their stability, activity, and trafficking (Salaun et al., 2020). Several de-palmitoylating enzymes have also been identified that act as

the 'erasers' of *S*-palmitoylation, and are divided into three classes: the acyl-protein thioesterases that

shuttle between the Golgi and cytosol (APTs; Vartak et al., 2014), the predominantly lysosomal palmitoyl-

protein thioesterases (PPTs; Koster and Yoshii, 2019) and the more recently discovered α/β hydrolase

domain-containing 17 proteins (ABHD17; Lin and Conibear, 2015). Unlike other post-translational

modifications, palmitoylation lacks a consensus substrate amino sequence, and the mechanisms that

govern ZDHHC enzyme-substrate interactions are controversial, with contrasting reports of substrate

interactions being both promiscuous and specific (Malgapo and Linder, 2021). Currently these interactions

are thought to be governed by the subcellular targeting of ZDHHCs enzymes and the presence of protein-

protein interacting motifs within the ZDHHC N- and C-termini, which are highly diverse among the ZDHHC

enzymes (Rana et al., 2018). Differential gene expression can also have a profound influence on protein

interactions and may play a role in the coordination of *S*-palmitoylation in the brain. However, a detailed

overview and analysis of the precise cellular and regional expression patterns of the palmitoylating and

de-palmitoylating enzymes has not yet been described, and as such, little is known about how this

expression is coordinated in the nervous system.

Recent advances in single-cell RNA sequencing (scRNAseq) techniques have enabled the

classification of neuronal and non-neuronal cell types in unprecedented detail, providing a better

understanding of cellular diversity and function in the nervous system, while also providing a means to

study the expression patterns of individual genes across an ever-expanding range of brain regions and

cellular classifications. Here, we capitalized on the recent surge in RNAseq publications characterizing

regional and cellular transcriptomics of the mouse nervous system. We curated and analyzed expression

data from a number of publicly available RNAseq mouse datasets to generate a detailed analysis of the

expression patterns of the genes associated with *S*-palmitoylation in the mouse brain. Furthermore, we

present an interactive web tool that allows user-driven interrogation of the expression patterns of

palmitoylating and de-palmitoylating enzymes from numerous collated studies across a variety of brain

regions and cell types (http://brainpalmseq.med.ubc.ca/). We demonstrate the utility of this resource by

detailing the considerable cell type and regional heterogeneity in expression patterns of these enzyme

families and their accessory proteins, revealing numerous cell type enrichments and co-expression

patterns that allowed us to generate and test hypotheses about palmitoylating enzyme-substrate

interactions.

Results

BrainPalmSeq: an interactive database to search palmitoylating and depalmitoylating enzyme expression in the mouse brain

The recent development of scRNAseq has revolutionized our understanding of the complex transcriptional diversity of neuronal and non-neuronal cell types in the brain. We found however, there were several barriers to the easy access for much of this data, with no single resource available to evaluate multi-study expression data. Data can also be difficult to access when studies are not accompanied by an interactive online web viewer, while datasets that do have a web viewer employ diverse interfaces that are often complex, particularly for large scRNAseq datasets. Furthermore, the differing study specific analysis pipelines, as well as the variety of data presentation formats in web viewers including heatmaps, bar charts, tables or t-SNE plots can make datasets difficult for non-bioinformaticians to interpret and compare. In order to remove these barriers and provide easy access to expression data for the proteins that regulate *S*-palmitoylation in the brain, we created 'BrainPalmSeq', an easy-to-use web platform allowing user driven interrogation of compiled multi-study expression data at cellular resolution through simple interactive heatmaps that are populated according to user selected brain regions, cell-types or genes of interest (http://brainpalmseq.med.ubc.ca/).

To create BrainPalmSeq we first curated three large datasets from whole-brain scRNAseq studies that were acquired through selection-free cell sampling to provide high resolution expression data covering hundreds of cell types at a variety of developmental ages (Rosenberg et al., 2018; Saunders et al., 2018; Zeisel et al., 2018). As scRNAseq has several caveats including low sensitivity and high frequency of dropout events leading to incomplete detection of expressed genes (Haque et al., 2017), we complemented these datasets where possible with curation of several bulk and pooled-cell RNAseq studies that used population-level ensemble measurements from whole-brain and region-specific studies. We further included selected studies for the major glial cell types and data from the most comprehensive neuron specific study performed to date by the Allen Institute (Supplementary File 1). Together, the datasets curated in BrainPalmSeq cover all major regions of the mouse nervous system across a variety of regional and cellular resolutions.

Expression data were extracted from selected studies for the 24 mouse ZDHHC genes (*Zdhhc1-Zdhhc25*, while *Zdhhc10* is omitted), as well as the best characterized de-palmitoylating enzymes (*Ppt1, Lypla1, Lypla2, Abhd17a, Abhd17b* and *Abhd17c*) and ZDHHC accessory proteins (*Golga7, Golga7b* and *Selk*). Where possible, data were processed from the raw transcripts or unique molecular identifier (UMI)

counts using the same normalization protocol to allow for more consistent evaluation of differences in

gene expression within datasets. We sampled from RNAseq datasets that used a diverse range of sample

collection, processing and analysis techniques, allowing for direct visualization of the relative expression

patterns of selected genes can be directly visualized within datasets. Users can then validate their

observations across complimentary whole brain or region/cell-type specific datasets included in

BrainPalmSeq. Dropdown menus allow for selection of individual ZDHHC genes or brain regions within

each dataset, while the hover tool reveals metadata for each cell type, including neurotransmitter

designations and marker genes. We provide download links to all expression data including cell type

metadata so that users can replot gene expression profiles in their preferred format. To demonstrate the

utility of this resource, we performed a detailed exploration of selected datasets from BrainPalmSeq,

revealing how expression patterns can give insights into the function of the palmitoylating and de-

palmitoylating enzymes in the mouse brain.

ZDHHC expression in the nervous system shows regional and cell-type specific patterning

We began by exploring BrainPalmSeq data curated from the 'MouseBrain' dataset, which provides

the broadest overview of expression patterns in the nervous system (Zeisel et al., 2018). This scRNAseq

study sampled multiple dissected regions from the adolescent (mean age ~P25) mouse central and

peripheral nervous systems (CNS and PNS, respectively), identifying 265 transcriptomically unique cell-

types (referred to herein as metacells) for which we plotted re-normalized ZDHHC expression values,

according to the hierarchical cell-type clustering established by the original study (Figure 1A). While

ZDHHC expression was detected in all regions of the nervous system, expression of the 24 ZDHHC genes

was highly variable across metacell types and clusters. We measured the mean ZDHHC expression within

each cluster to gain insight into which cell-types in the nervous system have the greatest overall

expression of palmitoylating enzymes. The heatmap rows and columns were ranked (sorted by

descending averages) to determine which cell-types had the highest expression of ZDHHCs, and which

ZDHHCs were most abundantly expressed across cell-types (Figure 1B). Mean ZDHHC expression was

particularly high in neurons of the PNS, along with cholinergic/monoaminergic and hindbrain neurons of

the CNS. Of the non-neuronal metacell clusters, oligodendrocytes had the highest ZDHHC expression,

while other glial cell-types appear at the lower end of the ranking (Figure 1B). *Zdhhc20* was the most

abundantly expressed ZDHHC, with the highest mean expression across all cell-type clusters, followed by

Zdhhc2, *Zdhhc17*, *Zdhhc3* and *Zdhhc21*, while expression of *Zdhhc11*, *Zdhhc19* and *Zdhhc25* were

negligible. We next clustered neuronal metacells of the PNS and CNS according to the neurotransmitter

expression combinations, revealing the highest mean ZDHHC expression was observed in neurons that

utilized acetylcholine and nitric oxide as co-neurotransmitters, with cholinergic neurons featuring near

the top of the list in several neurotransmitter combinations (Figure 1C). Monoaminergic neurons utilizing

noradrenaline and serotonin also generally ranked high in the list, consistent with the data in Figure 1B

that ranked cholinergic and monoaminergic neurons as the metacell cluster with the highest CNS ZDHHC

expression overall, indicating a higher propensity for these cell-types to utilize *S*-palmitoylation as a post-

translational mechanism to modify cellular signaling. We performed comparative analysis of ZDHHC

expression on another large-scale scRNAseq study of the mouse brain that sampled a variety of cortical

and subcortical structures of the adult mouse (P60-P70) (Saunders et al., 2018; 'DropViz'; Figure 1-figure

supplement 1A). We found expression patterns and enrichments to be similar across these two

independent, large scale scRNAseq studies, supporting the general trends observed within the

MouseBrain dataset.

To gain insight into the potential networks of ZDHHC enzymes that might work together to coordinate

S-palmitoylation in different cell types we performed co-expression analysis (Spearman correlation)

between ZDHHC genes across all 265 metacell types in the MouseBrain dataset (Figure 1D). Neuron

enriched *Zdhhc3*, *Zdhhc8*, *Zdhhc17* and *Zdhhc21* formed the strongest network of co-expression

associations, while glial cell enriched *Zdhhc2, Zdhhc9* and *Zdhhc20* formed less robust correlations with

other ZDHHCs. Weaker correlations were observed across the 565 cell-types in the DropViz dataset, which

may reflect the absence of the PNS neurons and glia in this study (Figure 1-figure supplement 1D).

In order to create a list of potential substrates for the ZDHHCs in the mouse nervous system, we

expanded our co-expression analysis to include all expressed genes from the 'MouseBrain' dataset that

had significant correlation (R > 0.7) with one or more ZDHHC. We identified 914 genes with expression

patterns that were significantly correlated with ZDHHCs. This list was cross-referenced with the mouse

SwissPalm database of *S*-palmitoylated substrates identified in at least one palmitoyl-proteome or

experimentally validated (SwissPalm annotated; Blanc et al., 2015, 2019). We found that genes that

showed correlated expression with a ZDHHC were significantly enriched with *S*-palmitoylation substrates,

indicating that ZDHHCs are more likely to be co-expressed with their *S*-palmitoylation substrates in the

brain (Figure 1E). Co-expression analysis of the 'DropViz' dataset revealed a similar enrichment of *S*-

palmitoylation substrates that were co-expressed with ZDHHCs (Figure 1-figure supplement 1E),

supporting the notion of ZDHHC enzyme-substrate co-expression. PANTHER GO analysis of the ZDHHC co-

expressed *S*-palmitoylation substrates curated from 'MouseBrain' revealed several significant

enrichments in GO terms for biological processes related to protein localization (Figure 1F). These findings

are consistent with the known role of *S*-palmitoylation in regulating protein localization and signaling

complexes at cellular membranes.

Heterogeneity in ZDHHC expression within excitatory neurons of the dorsal hippocampus

The hippocampus is a heavily studied brain region that is critical for learning and memory (Bird

and Burgess, 2008). A recent pooled-cell RNAseq study of excitatory neurons in the hippocampus revealed

extensive regional variability in gene expression profiles of the hippocampal tri-synaptic loop

(hipposeq.janelia.org; Cembrowski et al., 2016). In order to clearly visualize if ZDHHC expression also

varied within these different cell populations, we projected log transformed expression heatmaps

generated in BrainPalmSeq for the 'hipposeq' dorsal-ventral excitatory neuron dataset on to anatomical

maps of the dorsal hippocampus (Figure 2A). We observed considerable heterogeneity in the regional

expression patterns of the ZDHHCs in the hippocampus. Hierarchical clustering analysis revealed that the

ZDHHCs could be grouped into those that showed similar expression in all regions, those that were

dentate gyrus granule cell (DG) enriched, DG depleted or CA1/CA2 enriched (Figure 2B). We generated

comparative heatmaps for several scRNAseq studies curated in BrainPalmSeq that also quantified the

hippocampal excitatory neuron transcriptome and found similar cross-study expression patterns for many

of the ZDHHCs (Figure 2-figure supplement 1A). Furthermore, *in situ* hybridization data from the Allen

Institute showed a high degree of overlap with the 'hipposeq' derived ZDHHC expression patterns,

supporting the replicability of the expression patterns observed in the 'hipposeq' dataset (Figure 2-figure

supplement 1B; Supplementary File 2).

We next sought to utilize the 'hipposeq' dataset to determine if there might be regional

differences in the expression of *S*-palmitoylation substrates in excitatory neurons of the dorsal

hippocampus, which may be potential substrates for regionally enriched ZDHHC enzymes. To investigate

the regionally enriched predicted hippocampal palmitoylome, we utilized the enrichment analysis tools

built in to hipposeq.janelia.org (see Materials and Methods). Neurons in each hippocampal sub-region

expressed unique *S*-palmitoylation substrates that were related to highly divergent functions. We found

for CA1 neurons, which have the highest expression of *Zdhhc2*, *Zdhhc17*, *Zdhhc23* and *Zdhhc9* (Figure 2C),

the CA1 enriched predicted palmitoylome (Figure 2D) generated KEGG pathways related to 'Calcium

signaling', 'Glutamatergic synapse' and 'Long term potentiation', supporting the known role for *S*-

palmitoylation in CA1 hippocampal synaptic plasticity (Figure 2E; Ji and Skup, 2021; Matt et al., 2019). The

CA1 predicted palmitoylome was composed of around 46 % synaptic proteins (SynGO annotated), with

SynGO ontologies related to 'synaptic vesicle exocytosis' and 'synapse organization' (Figure 2F; Koopmans

et al., 2019). In contrast, the predicted palmitoylome of DG granule cells which have the highest

expression of *Zdhhc21*, *Zdhhc4*, *Zdhhc24* and *Zdhhc8* (Figure 2G, H) generated KEGG pathways related to

'Ribosome', 'Cholinergic synapse' and 'Parkinson's disease' (Figure 2I). The DG predicted-palmitoylome

was composed of 29 % synaptic proteins (SynGO annotated), with SynGO ontologies related to 'protein

translation at presynapse' and 'protein translation at postsynapse', revealing a potential role for

palmitoylating enzymes in regulating translation in this cell-type that has not yet been studied (Figure 2J).

Together, we have described patterns of restricted expression of ZDHHC enzymes and *S*-palmitoylation

substrates in the dorsal mouse hippocampus, and generated regionally-enriched predicted-

palmitoylomes that provide insight into the role of *S*-palmitoylation in neuronal function in each of these

hippocampal sub-regions.

Neocortical ZDHHC expression is partially segregated across cortical layers and neuronal subclasses

We next examined scRNAseq datasets curated in BrainPalmSeq from the cortex, beginning with a

study of the primary somatosensory cortex (SSp; Zeisel et al., 2015). We projected heatmaps of pyramidal

excitatory neuron ZDHHC expression generated in BrainPalmSeq onto cortical layer diagrams of SSp, again

revealing anatomically heterogeneous excitatory neuron expression patterns for several of the ZDHHC

transcripts. Clustering primarily grouped the enzymes according to expression levels, with *Zdhhc21*,

Zdhhc17 and *Zdhhc8* displaying the highest relative expression (Figure 3B). *Zdhhc2*, *Zdhhc3* and *Zdhhc20*

expression was also high, with the remainder of the ZDHHCs having moderate to low expression. We

compared these expression patterns with other datasets curated in BrainPalmSeq (Figure 3-figure

supplement 1A), which revealed many consistent patterns of expression maintained across several

independent studies. For example, multiple studies reported high expression of *Zdhhc8* in cortical Layer

2/3, enrichment of *Zdhhc2* in Layer 4 and elevated expression of *Zdhhc21* in all layers, particularly in Layer

5. *Zdhhc3* and *Zdhhc20* were also broadly expressed in all cortical layers across studies. Similar patterns

were seen in the SSp region from available in situ hybridization studies from Allen Brain Institute (Figure

3-figure supplement 1B).

We examined expression patterns of the ZDHHC enzymes from one of the largest neuronal

scRNAseq studies from the isocortex performed by the Allen Brain Institute, which identified 236

glutamatergic and 117 GABAergic distinct neuron metacell types (Yao et al., 2021). We averaged ZDHHC

expression data downloaded from BrainPalmSeq for the major metacell clusters from all regions of the

isocortex, according to their anatomical location and/or axon projection and plotted ranked heatmaps

(Figure 3C,D). We again found that *Zdhhc20* was the ZDHHC transcript with the highest expression, with

broad expression across the majority of glutamatergic and GABAergic cell-types. Elevated expression of

Zdhhc14 was found in both glutamatergic and GABAergic neurons, which was moderately expressed in

other studies of the brain and cortex discussed previously. Numerous subtypes of projection neurons

featured at the top of the ranking including pyramidal tract (PT) projecting neurons found in layer 5 of the

cortex, that have extensive dendritic branching and long-range axonal projections to the spinal cord,

brainstem and midbrain, as well as the ipsilateral cortex, striatum and thalamus. Other neuron subtypes

with high ZDHHC expression included a number of intratelencephalic (IT) projecting neuron classes,

including those from Layer 4/5 of the temporal/perirhinal/ectorhinal/entorhinal cortices, Car3 expressing

Layer 6 neurons, Layer 6b neurons, and Cortex IT projecting neurons from all cortical layers (Harris and

Shepherd, 2015; Yao et al., 2021). GABAergic neurons of the isocortex also showed elevated expression

of the common neuronal ZDHHCs including *Zdhhc2*, *Zdhhc3*, *Zdhhc14*, *Zdhhc17*, *Zdhhc20* and *Zdhhc21*.

The highest mean ranked expression was observed in the recently categorized Sncg neurons that

correspond to Vip^+/Cck^+ multipolar or basket cells (Tasic et al., 2018), and lowest expression was observed

in the Vip subclass of interneurons.

Together, our observations reveal that the complex transcriptional diversity of neurons that has

recently been revealed by RNA sequencing also includes heterogeneity in the expression of the ZDHHC

enzymes that mediate palmitoylation. These expression patterns are likely to influence enzyme-substrate

interactions along with the function of *S*-palmitoylation substrates, and thus influence neuronal

development, function and synaptic plasticity.

De-palmitoylating enzyme and ZDHHC accessory protein expression in the nervous system shows
regional and cell-type specific patterning

Dynamic turnover of protein *S*-palmitoylation is mediated by the activity of de-palmitoylating

enzymes, which determine the half-life of *S*-palmitoylation on a target protein. These include acyl-protein

thioesterases 1 and 2 (APT1, APT2; encoded by *Lypla1*, *Lypla2*), palmitoyl-protein thioesterase 1 (PPT1)

and the more recently identified α/β hydrolase domain-containing 17 proteins (ABHD17A, ABHD17B and

ABHD17C). Compared with the ZDHHC enzymes, relatively less is known about the substrates, sub-cellular

localization and brain expression patterns of this family of enzymes. We next explored BrainPalmSeq to

determine which cell-types/brain regions show the highest expression of de-palmitoylating enzymes.

We first examined expression heatmaps for the known de-palmitoylating enzymes across the 265

cell-types identified in the 'MouseBrain' dataset (Figure 4A) and the cell-type averages for the 565 cell-

types from the 'DropViz' dataset (Figure 4-figure supplement 1A). *Ppt1* and *Abhd17a* were the enzymes

with the broadest expression across all cell-types, with *Ppt1* expression being notably elevated in neurons

of the hindbrain and immune cells, and *Abhd17a* being elevated in hindbrain neurons, sensory neurons,

oligodendrocytes and epithelial cells. Ranked expression (sorted by descending averages) of de-

palmitoylating enzymes in the 'MouseBrain' (Figure 4B) and 'DropViz' (Figure 4-figure supplement 1B)

datasets classified oligodendrocyte lineage cells among the cell-types with the highest expression of de-

palmitoylating enzymes overall, primarily due to elevated expression of *Abhd17b*. This mirrors

oligodendrocyte enrichment of ZDHHC enzyme expression, again indicating that dynamic regulation of *S*-

palmitoylation may be particularly important in this cell type. *Lypla2* expression was greater than *Lypla1*

overall in the brain, with *Lypla2* expression being highest in neurons and ependymal cells (Figure 4-figure

supplement 1A). *Abhd17c* had the lowest brain expression of all the de-palmitoylating enzymes studied.

Correlation analysis between the ZDHHCs and de-palmitoylating enzymes revealed numerous instances

of co-expression with almost every ZDHHC (Figure 4D), revealing potential cooperative pairs of

palmitoylating and de-palmitoylating enzymes in the nervous system.

Although the ZDHHC enzymes are thought to act autonomously, several accessory proteins have

been discovered that can regulate ZDHHC stability, localization and catalytic activity (Salaun et al., 2020).

These include GOLGA7 (GCP16), which can bind to ZDHHC9 and enhance both protein stability and

enzymatic activity by stabilizing the ZDHHC9 auto-palmitoylated intermediate that is formed prior to

palmitate transfer from the enzyme to the substrate protein (Mitchell et al., 2014; Swarthout et al., 2005).

Both GOLGA7 and related isoform GOLGA7B are also able to interact with ZDHHC5, with the latter

influencing ZDHHC5 plasma membrane localization (Woodley and Collins, 2019). Finally, SELK (SELENOK;

Selenoprotein K) is an ER localized protein that was found to interact with ZDHHC6, stabilize the auto-

palmitoylated intermediate and increase palmitoylation of substrate proteins including the IP$_3$ receptor

(Fredericks et al., 2017, 2014). We observed widespread expression of *Selk* across all cell-types, with

expression being considerably higher than any of the ZDHHCs, de-palmitoylating enzymes or other

accessory proteins (Figure 4A, S4A). This is consistent with the known functions of SELK in the ER

associated protein degradation pathway and regulation of ER calcium flux (Pitts and Hoffmann, 2018).

Golga7b expression was widespread across neuronal subtypes but barely detected in glial cells (Figure 4A,

S4A). Accordingly, *Golga7b* expression was also strongly correlated with several of the ZDHHCs that were

most highly expressed in neurons, including *Zdhhc3*, *Zdhhc8*, *Zdhhc17* and *Zdhhc21* (Figure 4D). In

contrast, *Golga7* was enriched in glial cells, particularly in oligodendrocytes, similar to ZDHHC9 for which

GOLGA7 is a key accessory protein (Figure 4A, S4A). GOLGA7 and GOLGA7B share 61% amino acid

similarity, but their expression was either not correlated or was negatively correlated, indicating that the

ZDHHC association of each of these proteins may be regulated in part by differential expression.

Loss of function mutations in palmitoylating and de-palmitoylating enzymes

Impaired regulation of *S*-palmitoylation has been implicated in numerous neurological disorders,

many of which are due to loss of function (LOF) mutations in the genes encoding palmitoylating and de-

palmitoylating enzymes (Cho and Park, 2016; Matt et al., 2019). We next sought to determine if the

regional and cell type expression data available in BrainPalmSeq could reveal insights into the

pathogenesis of disorders caused by LOF mutations in palmitoylating and de-palmitoylating enzymes. As

many of these diseases have a neurodevelopmental origin, we examined whole brain datasets curated in

BrainPalmSeq from the neonatal (Rosenberg et al., 2018), adolescent (Zeisel et al., 2018) and adult

(Sjöstedt et al., 2020) mouse brain.

A single nucleotide polymorphism (SNP) in the *ZDHHC8* gene has been implicated in increased

susceptibility to schizophrenia (Chen et al., 2004; Mukai et al., 2004), while hemizygous microdeletion in

the chromosomal locus 22q11, which encodes a number of genes including *ZDHHC8*, is one of the highest

known genetic risk factors to developing schizophrenia (Figure 5A; Karayiorgou et al., 2010). To assess the

developmental expression of *Zdhhc8*, we averaged expression within broadly defined cell-type clusters

that could be applied to both the Rosenberg and Zeisel scRNAseq datasets (Figure 5A, B; Supplementary

File 3). *Zdhhc8* expression was highest in neurons of the cortex and hippocampus, followed by neurons of

the mid- and hindbrain at both developmental ages. To explore regional expression in the adult mouse

brain, we projected BrainPalmSeq generated heatmaps expression data from the 'Protein Atlas' mouse

whole brain dataset (bulk RNAseq from major brain regions; Figure 5-figure supplement 1) onto

anatomical maps of the mouse brain, again revealing highest expression of *Zdhhc8* in the cortex, followed

by the hippocampus and basal ganglia (Figure 5C; Sjöstedt et al., 2020). *Zdhhc8* expression was particularly

enriched in Layer 2/3 of the neonatal (not shown) and adult mouse (Figure S3B) cortex, which is the

cortical layer with the most pronounced morphological deficits in patients with Schizophrenia (Glantz and

Lewis, 2000; Kolluri et al., 2005; Wagstyl et al., 2016). Together, we found *Zdhhc8* expression patterns in

the mouse brain that are established early in postnatal development and maintained into adulthood, that

also overlay with many brain regions and cell types that are known to be severely affected in patients with

schizophrenia. These observations support a model in which LOF *ZDHHC8* mutations may elicit many of

the symptoms of schizophrenia by disrupting *S*-palmitoylation and normal neuronal development in these

brain regions.

Mutations in the *ZDHHC9* gene, which is located on the X chromosome, have been identified in
~2% of individuals with X-linked intellectual disability (ID) (Raymond et al., 2007; Tzschach et al., 2015).
Neuroanatomical abnormalities reported in patients with *ZDHHC9* mutations include decreased cortical,
thalamic and striatal volume, as well as widespread white matter abnormalities with prominent
hypoplasia (under-development) of the corpus callosum (Baker et al., 2015; Bathelt et al., 2016).
Disrupted white matter integrity is thought to underlie deficits in global and local brain connectivity in
patients with *ZDHHC9* mutations (Bathelt et al., 2017). *Zdhhc9* knock-out mice also develop similar
pathological changes, including decreased volume of the corpus callosum (Kouskou et al., 2018). We
observed considerable cell-type enrichment of *Zdhhc9* in oligodendrocytes across studies and
developmental ages (Figure 5D, E), accompanied by moderate neuronal expression of *Zdhhc9* relative to
other ZDHHCs across several brain regions including the hippocampus and cortex (Figure 2A, 3A, 5D, E),
consistent with the known function of ZDHHC9 in regulating neuronal development (Shimell et al., 2019).
Regionally, we found *Zdhhc9* expression in adult mice to be highly enriched in the corpus callosum, the
largest white matter tract in the brain (Figure 5F). As myelin production by oligodendrocytes is critical for
maintaining white matter integrity, these observations indicate that disrupting *S*-palmitoylation in
oligodendrocytes may underlie the white matter pathology and decreased connectivity observed in
patients with X-linked ID and *ZDHHC9* mutations.

Infantile neuronal ceroid lipofuscinosis (INCL or CLN1 disease) is a severe neurological disorder
caused by LOF mutations in the *PPT1* gene that presents in the first 6 - 12 months of life and is
characterized by rapid developmental regression, blindness and seizures, with continual deterioration
until death in early childhood (Nita et al., 2016). While PPT1 is thought to primarily localize to lysosomes
with an essential role in lysosomal degradation of *S*-palmitoylated proteins (Lu et al., 1996), this protein
also has a synapse-specific function in regulating synaptic vesicle cycling and synaptic transmission (Koster
and Yoshii, 2019). We found that neuronal *Ppt1* expression was high in postnatal neurons of the spinal
cord, olfactory bulb and mid/hindbrain, while microglia were the highest expressing non-neuronal cell
type at both postnatal ages (Figure 5G, H). Neurodegeneration has been detected in the spinal cord prior
to onset within the brain in *Ppt1* knock-out mice, accompanied by extensive glial cell activation including
microgliosis, which is a pathological hallmark of CLN1 disease (Shyng et al., 2017). Mid-/hindbrain neurons
also had high expression of *Ppt1,* consistent with reports that *Ppt1* knock-out mice show early signs of
brain pathology in the thalamus (Kielar et al., 2007). Overall, we observed widespread *Ppt1* expression in
almost every brain region in adult mice, consistent with the sweeping neurological deficits associated with

CLN1 disease (Figure 5I). Together, these observations reveal how the loss of *Ppt1* in cell types with high

Ppt1 expression may lead to cell death/dysfuntion in the early stages of CLN1 disease.

ZDHHC cell type enrichments can be used to predict and validate ZDHHC substrates

We next tested if ZDHHC expression patterns identified from BrainPalmSeq could be used to

predict and validate *S*-palmitoylation substrates for regionally enriched ZDHHCs. We focused on *Zdhhc9*,

which showed a consistent cell-type enrichment in oligodendrocytes across multiple studies in

BrainPalmSeq, while LOF mutations in *ZDHHC9* are known to result in reduced white matter integrity in

the brain (Raymond et al., 2007). Examination of the Marques et al oligodendrocyte-specific scRNAseq

dataset curated in BrainPalmSeq revealed that oligodendrocyte *Zdhhc9* expression increased throughout

maturation, with highest expression in the myelin forming (MFOL) intermediate-maturity subtype of

oligodendrocytes, while slightly lower expression is maintained in mature oligodendrocytes (MOL; Figure

6A; Marques et al., 2016).

To identify potential substrates for ZDHHC9, we cross-referenced a list of MFOL/MOL enriched genes

identified in the study by Marques et al (Marques et al., 2016) with the SwissPalm database to identify

known palmitoylation substrates in these cell types (Swiss Palm Annotated; Figure 6B; Blanc et al., 2019,

2015). PANTHER analysis of cellular component enrichments for these substrates revealed the most

significant enrichment was for the term 'myelin sheath' (30 proteins; Figure 6C, Figure 6-figure

supplement 1). To determine if any of the myelin sheath associated proteins could be palmitoylated by

ZDHHC9, we selected three proteins (MOBP, PLP1 and CNP) for experimental validation (Figure 6C). We

separately expressed each of these candidate substrates together with ZDHHC9 and its accessory protein

GOLGA7 in HEK293T cells, and determined the proportion of palmitoylated substrate using an acyl-resin

assisted capture (acyl-RAC) palmitoylation assay (Forrester et al., 2011). In this assay, free cysteine

residues of cell lysates were first blocked, followed by cleavage of the palmitoyl-thioester bond with

hydroxylamine, resulting in the exposure of a free sulfhydryl group. Cleaved lysates were then applied to

a Sepharose resin to capture palmitoylated proteins containing a free sulfhydryl group. Un-bound proteins

(Unpalm Fraction) were first extracted from the resin mixture, followed by elution of bound palmitoylated

proteins from the resin (Palm Fraction). To assess non-specific binding of unpalmitoylated protein to the

resin, half of the cell lysate was processed without the cleavage step (NSB control). Co-expression of HA-

ZDHHC9 and FLAG-GOLGA7 increased the palmitoylated fraction of MOBP and PLP1, indicating that these

proteins are substrates for ZDHHC9 (Figure 6D, E, G). Conversely, CNP was not identified as a ZDHHC9

substrate in our assay (Figure 6F, G). These results demonstrate how the cell-type enrichments of ZDHHC

enzymes identified in this study can be used, along with the lists of similarly enriched palmitoylation
substrates, to guide the identification of enzyme-substrate interactions that can be further investigated
in vivo.

Discussion

BrainPalmSeq as a tool to generate hypotheses about proteins that control S-palmitoylation in the
brain

We have demonstrated the utility of BrainPalmSeq by providing examples of how this database
can be used to explore detailed region and cell type-specific expression patterns of the known
palmitoylating and de-palmitoylating enzymes, and their accessory proteins. We reveal how these
expression patterns can be used to predict/validate *S*-palmitoylation substrates and better understand
diseases associated with loss of function mutations in the enzymes that mediate *S*-palmitoylation. Given
the number of brain regions and cell types incorporated into BrainPalmSeq that were not discussed in the
present study, including the thalamus, hypothalamus, amygdala, striatum and cerebellum, there is rich
potential for users to explore the data and generate hypotheses about the role of these enzymes in the
brain.

Insights into the role of *S*-palmitoylation associated enzymes in brain physiology and pathology

While we found that many of the proteins we studied showed correlated expression across the
entire mouse nervous system, particularly those enriched in neurons including *Zdhhc3*, *Zdhhc8*, *Zdhhc17*
and *Zdhhc21*, expression of these genes was segregated within more narrowly defined neuronal
populations such as the excitatory pyramidal neurons within the hippocampal tri-synaptic loop or layers
of the somatosensory cortex. This is in line with the extensive neuronal transcriptional heterogeneity
identified recently by a number of scRNAseq studies (Saunders et al., 2018; Yao et al., 2021; Zeisel et al.,
2015, 2018). The genes that determine neuronal identity fall under four broad functional categories: those
that control transcriptional programs, membrane conductance, neurotransmission, or synaptic
connectivity (Zeisel et al., 2018). We also report heterogeneity in the neuronal fingerprint of
palmitoylating and de-palmitoylating enzyme expression, which will in turn give rise to differential *S*-
palmitoylation of neuronal proteins. Future work is needed to determine how these specific ZDHHC
expression patterns are related to dynamic *S*-palmitoylation in these neuronal sub-types, and how the
elevated expression of certain ZDHHCs can alter neuronal function. Given that *S*-palmitoylation is a key
regulator of neuronal development, and that nearly half of all known synaptic proteins are substrates for

palmitoylation (Sanders et al., 2015), this heterogeneity is likely to be a key mechanism in the fine tuning

of neuronal function and synaptic transmission.

Many of the ZDHHCs that we observed with consistently elevated expression across multiple

studies in BrainPalmSeq have already been studied in the context of neuronal signaling, including ZDHHC2,

ZDHHC3, ZDHHC8 and ZDHHC17 (Ji and Skup, 2021; Matt et al., 2019). In contrast, ZDHHC20 and ZDHHC21

are relatively understudied in the nervous system, despite our observation that these are two of the most

abundantly expressed ZDHHCs across neuronal cell types, with broad expression of *Zdhhc20* also in glial

cells. A recent study defined a role for ZDHHC21 in the palmitoylation of serotonergic receptor 5-HT1A

and implicated downregulation of ZDHHC21 in the development of major depressive disorder (Gorinski et

al., 2019). Interestingly, both ZDHHC20 and ZDHHC21 have a potential role in the pathogenesis of

Alzheimer's disease, as they can palmitoylate BACE1, Tau and amyloid precursor protein (Cho and Park,

2016). Further work is required to understand the likely important role of these enzymes in the brain.

We made several other interesting observations during our examination of BrainPalmSeq that

were not discussed in detail in the present study but we believe warrant further investigation. For

example, the particularly elevated expression of *Zdhhc2* in peripheral sensory neurons may indicate an

important role for palmitoylation in this cell type. Across multiple studies we observed striking enrichment

of *Zdhhc14* in cerebellar Purkinje neurons, a cell type in which *S*-palmitoylation is known to be important

for long-term depression, although the role of ZDHHC14 in this process has not yet been investigated

(Thomas et al., 2013). *Zdhhc23* was similarly enriched in the CA2 region of the hippocampus, with

comparatively low expression across other cell types. More broadly, the elevated expression of a variety

of palmitoylating enzymes in neurons that utilize acetylcholine or monoamines as neurotransmitters

would suggest an important role for *S*-palmitoylation in these neurons that has yet to be explored.

Accordingly, many of the key proteins involved in cholinergic synaptic transmission are *S*-palmitoylation

substrates including muscarinic acetylcholine receptor M2 (CHRM2), acetylcholinesterase (ACHE) and

ATP-citrate synthase (ACLY; Blanc et al., 2015, 2019). Our observations of co-enrichment of certain

palmitoylating and de-palmitoylating enzymes are also of interest, such as *Abhd17b* and *Zdhhc9* in

oligodendrocytes. It is possible that these enzymes share substrates to mediate dynamic

palmitoylation/de-palmitoylation, or conversely, have separate substrates in order to maintain stable *S*-

palmitoylation states of certain oligodendrocyte expressed proteins. Importantly, the data accessibility in

BrainPalmSeq will enable researchers to develop hypotheses regarding their cell type, brain region or

protein of interest.

The palmitoylome of each cell type in the nervous system is likely to be highly heterogeneous and
will be determined by the expression of both the *S*-palmitoylation substrates and the palmitoylating and
de-palmitoylating enzymes in a given cell type. Furthermore, accumulating evidence has revealed that
this palmitoylome can be altered by extrinsic factors such as chronic stress and neuronal activity (Kang et
al., 2008; Zareba-Koziol et al., 2019). While we have provided predicted palmitoylomes composed of
several highly expressed or enriched *S*-palmitoylation substrates in select brain regions and cell types,
experimental validation to reveal the relative palmitoylation of substrates under various conditions is
needed to fully understand these cellular differences. Nevertheless, we were able utilize our predicted
palmitoylomes to validate substrates for ZDHHC9, providing insight into the potential role of this enzyme
in myelin regulation in the brain.

Neurological disorders that arise from LOF gene mutations may be predicted to lead to
pathological changes that are more severe in the brain regions in which these genes are most highly
expressed. We observed this type of regional overlay for the expression patterns of *Zdhhc8*, *Zdhhc9* and
Ppt1. Numerous other brain disorders are thought to be exacerbated by an imbalance in *S*-palmitoylation,
such as decreased *S*-palmitoylation of HTT in Huntington's disease (Virlogeux et al., 2021; Yanai et al.,
2006), increased *S*-palmitoylation of APP and TAU in Alzheimer's disease (Cho and Park, 2016), and
reduced *S*-palmitoylation of 5-HTA receptor in major depressive disorder (Gorinski et al., 2019). Efforts
are already underway to normalize aberrant *S*-palmitoylation in neurological diseases in order to improve
clinical outcomes (Roberts et al., 2012; Virlogeux et al., 2021). Understanding the brain expression
patterns of the enzymes that mediate palmitoylation in these diseases will be paramount to developing
and targeting such therapeutics.

Differential gene expression as a means to control *S*-palmitoylation in the brain
The mechanisms that govern ZDHHC enzyme-substrate interactions are complex and still not fully
understood. While the majority of post-translational modifications including phosphorylation and N-
glycosylation are highly sequence specific (Schwarz and Aebi, 2011; Ubersax and Ferrell, 2007), several
studies have revealed that *S*-palmitoylation by ZDHHCs can be stochastic, proximity based and lacking in
stereo-selectivity (Rocks et al., 2010; Rodenburg et al., 2017). Contrasting studies have shown that
numerous ZDHHCs have specific protein interacting domains including ankyrin repeat (AR), PDZ and SH3
domains that facilitate substrate interactions, providing support for a model in which more specific
enzyme-substrate interactions can govern *S*-palmitoylation (Abrami et al., 2017; Lemonidis et al., 2015;
Plain et al., 2020; Rana et al., 2018; Thomas et al., 2012; Verardi et al., 2017). Furthermore, a recent study

found striking substrate specificity for several ZDHHCs with the G-protein subunit Gαo, and revealed

intriguing observations that the subcellular localization of a number of *S*-palmitoylation substrates could

be controlled by changing the localization, and importantly, the expression of certain ZDHHC enzymes. In

this study, *S*-palmitoylated substrates were found to accumulate in the subcellular compartment in which

their partner ZDHHCs were targeted (Solis et al., 2020). This is particularly relevant as the ZDHHCs are

known to have diverse subcellular localizations including the Golgi, ER, endosomes and plasma membrane

(Globa and Bamji, 2017). Transcriptional control of differentially compartmentalized palmitoylating and

de-palmitoylating enzymes could therefore be an essential mechanism for regulating the subcellular

localization, and function, of *S*-palmitoylated protein substrates. Accordingly, LOF mutations in certain

ZDHHC enzymes leads to cell type-specific disruption in *S*-palmitoylation that is not compensated by other

members of the large ZDHHC family. We provide a means to investigate the expression of the proteins

that mediate *S*-palmitoylation, making BrainPalmSeq an invaluable resource to both researchers and

clinicians that are working to better understand the role of *S*-palmitoylation in the brain.

Figure Legends

Figure 1. Heterogeneous ZDHHC expression in the mouse nervous system

(A) Heatmap showing expression for the 24 ZDHHC genes, extracted from scRNAseq study of mouse CNS
and PNS (Zeisel et al., 2018). Each column represents one of the 265 metacells classified in the study.
Metacells are organized along x-axis according to hierarchical clustering designations generated by Zeisel
et al. Full metadata for this study available on BrainPalmSeq.

(B) Heatmap showing mean ZDHHC expression per hierarchical cluster, with columns and rows sorted by
descending mean ZDHHC expression per row/column.

(C) Heatmap showing mean ZDHHC expression per neurotransmitter cluster for all PNS and CNS neurons.
Columns and rows are sorted as in B.

(D) Correlation network showing ZDHHC co-expression across all metacells in 'MouseBrain' (Spearman R
> 0.5). Numbers in nodes correspond to ZDHHC number. Node color represents mean expression across
all metacells. Edge thickness represents strength of correlation.

(E) Graph showing proportion of genes from 'MouseBrain' dataset that are co-expressed with one or more
ZDHHC and also substrates for *S*-palmitoylation (SwissPalm annotated). 'Brain expressed' *n* = 15,389
protein coding genes expressed in the postnatal mouse brain, curated from the MGI RNAseq studies
database. 'R > 0.7 ZDHHC co-expressed' *n* = 914 genes co-expressed with one or more ZDHHC (Spearman
R > 0.7). 'R > 0.8 ZDHHC co-expressed' *n* = 167 genes co-expressed with one or more ZDHHC (Spearman R
> 0.8). Brain expressed vs. R > 0.7: $p < 0.001$; R > 0.7 vs R > 0.8: $p < 0.01$; Fisher's exact test.

(F) Graph of GO biological process analysis. Gene IDs from the 'MouseBrain' dataset (Zeisel et al., 2018)
that showed correlated expression with one or more ZDHHC (R > 0.7) and were also Uniprot reviewed and
SwissPalm annotated were used as input.

Units for all heatmaps in figure: mean log2(counts per 10,000 + 1).

Figure 2. Diversity in ZDHHC expression and S-palmitoylation substrate expression in the hippocampus

(A) Heatmap of excitatory neuron ZDHHC expression from dorsal hippocampus (original pooled cell
RNAseq data from Cembrowski et al., 2016) projected onto diagrams of dorsal hippocampus.

(B) Hierarchical clustering of ZDHHC expression data in A.

(C) Heatmap showing top 6 ranked expressing ZDHHCs in dorsal CA1 in descending order.

(D) Pie chart showing proportion genes with enriched expression in dorsal CA1 (dCA1) that are also
substrates for palmitoylation (SwissPalm annotated).

(E) KEGG analysis of the dCA1 enriched/SwissPalm annotated genes.

(F) SynGO analysis of the dCA1 enriched/SwissPalm annotated genes.

(G-J) As in (C)-(F) but for the dorsal dentate gyrus (dDG).

Heatmap legend in (A) applies to all heatmaps (logFKPM+1).

Figure 3. Pyramidal neuron layer specific ZDHHC expression

(A) Heatmap of excitatory neuron ZDHHC expression from somatosensory cortex (original data scRNAseq data from Zeisel et al., 2015) projected onto diagrams of cortical layers.

(B) Hierarchical clustering of ZDHHC expression data in A. Heatmap units in (A, B): mean log2(counts per 10,000 + 1)

(C) Heatmap of scRNAseq data from Allen Brain 10X genomics (Yao et al., 2021). Data are represented as mean ZDHHC expression per excitatory neuron subtype, with columns and rows sorted by descending mean ZDHHC expression per row/column.

(D) As in (C) but for inhibitory neuron subtypes. Heatmap units for (C, D): trimmed mean (25%-75%) Log2(CPM+1)

Figure 4. Heterogeneous de-palmitoylating enzyme and ZDHHC accessory protein expression in the mouse nervous system

(A) Heatmap showing expression of de-palmitoylating enzymes (top) and ZDHHC accessory subunits (bottom), extracted from scRNAseq study of mouse CNS and PNS (Zeisel et al., 2018). Each column represents one of the 265 metacells classified in the study. Metacells are organized according to hierarchical clustering designations generated by Zeisel et al.

(B) Heatmap showing mean de-palmitoylating enzyme expression per hierarchical cluster, with columns and rows sorted by descending mean ZDHHC expression per row/column.

(C) As B but for ZDHHC accessory proteins.

(D) Correlation network showing ZDHHC co-expression with de-palmitoylating enyzmes and accessory proteins across all metacells in 'MouseBrain' (Spearman R > 0.4). Node color represents mean expression across all metacells. Edge thickness represents strength of correlation.

Figure 5. Disease associated palmitoylating enzyme regional and cell-type expression overlays with brain pathology in associated LOF disorders

(A) Heatmap showing ranked *Zdhhc8* expressing neuronal and glial cell types in descending order. Original data from scRNAseq neonatal mouse brain study; Rosenberg et al., 2018. Cell types were averaged as described in Supplementary File 3. Heatmap units: mean log2(counts per 10,000 + 1).

(B) As in A, but original data from scRNAseq adolescent mouse brain study Zeisel et al (2018). Heatmap units: mean log2(counts per 10,000 + 1).

(C) Heatmap of *Zdhhc8* expression from whole brain regional bulk RNAseq data (original data from 'Protein Atlas'; Sjöstedt et al., 2020) projected onto anatomical map of mouse brain. Heatmap units: pTPM.

(D-F) As in (A)-(C) but for *Zdhhc9*.

(G-I) As in (A)-(C) but for *Ppt1*.

Figure 6. Validation of predicted *S*-palmitoylation substrates of *Zdhhc9* derived from cell-type enriched expression

(A) Graph of expression data for *Zdhhc9* extracted from BrainPalmSeq. Original data from oligodendrocyte scRNAseq study by Marques et al. Expression units: mean log2(counts per 10,000 + 1).

(B) Diagram illustrating workflow to generate a list of oligodendrocyte enriched palmitoylation substrates, GO annotated for myelin sheath for experimental validation.

(C)   STRING diagram of myelin sheath annotated palmitoylation substrates.

(D) Western blot following Acyl-RAC palmitoylation assay in HEK293 cells to identify palmitoylated and unpalmitoylated fractions of FLAG-MOBP either without or with co-transfection of FLAG-GOLGA7 and HA-ZDHHC9. Input = unprocessed protein lysate. NSB control = non-specific binding of unpalmitoylated protein to sepharose resin in control pipeline. Palm fraction = palmitoylated protein (bound to sepharose resin). Unpalm fraction = unpalmitoylated protein (did not bind to sepharose resin).

(E-F) As in (D) but for FLAG-PLP1 (E) or FLAG-CNP (F).

(G) Graphs quantifying the ratio of palmitoylated to unpalmitoylated protein either with or without co-transfections with FLAG-GOLGA7 and HA-ZDHHC9. *n* = 4-6 HEK cell cultures per condition. Statistics shown for palmitoylated fraction. Two-way ANOVA; Šídák's *post hoc*; mean ± SEM. MOBP: p = 0.0004, 95% CI -0.6594 to -0.2266; PLP1: p = 0.0046, 95% CI -0.1660 to -0.03011; CNP: p = 0.6981, 95% CI -0.3274 to 0.1742.

Source Data Legends

Figure 1 – Source data 1. ZDHHC expression in the mouse nervous system

Figure 2 – Source data 1. ZDHHC expression and S-palmitoylation substrate expression in the hippocampus

Figure 3 – Source data 1. ZDHHC expression cortical neurons

Figure 4 – Source data 1. De-palmitoylating enzyme and ZDHHC accessory protein expression in the mouse nervous system

Figure 5 – Source data 1. Disease associated palmitoylating enzyme regional and cell-type expression patterns

Figure 6 – Source data 1. Validation of predicted *S*-palmitoylation substrates of *Zdhhc9*

Materials and Methods

Data processing for BrainPalmSeq

For Zeisel et al., 2018 ('MouseBrain'), single-cell counts (UMI from 3' end counting) were downloaded from MouseBrain.org (loom file named l5_all.loom), and log normalized by first scaling the expression values provided to a sum of 10,000 per cell before calculating log2(scaled_counts+1). Averages were then performed by brain region, neurotransmitter and taxonomy for each gene.

For DropVIz Metacell counts were downloaded from DropViz.org (count file metacells.BrainCellAtlas_Saunders_version_2018.04.01.RDS and annotation file annotation.BrainCellAtlas_Saunders_version_2018.04.01.RDS) and log normalized by first scaling the expression values provided to a sum of 10,000 per metacell before calculating log2(scaled_counts+1). Averages were then performed by cell type, tissue and class for each gene. Genes associated with palmitoylation were selected in order to create the heatmaps.

For Zeisel, single-cell counts (UMI from 3' end counting) were downloaded from https://storage.googleapis.com/linnarsson-lab-www-blobs/blobs/cortex/expression_mRNA_17-Aug-2014.txt, and log normalized by first scaling the expression values provided to a sum of 10,000 per cell before calculating log2(scaled_counts+1). Averages were then performed by cluster, tissue and class for each gene. Genes associated with palmitoylation were selected in order to create the heatmaps, categories comprising fewer than 5 single cells are not displayed.

For Marques, single-cell counts (UMI from 3' end counting) were downloaded from GEO with accession ID GSE75330 (file GSE75330_Marques_et_al_mol_counts2.tab) and log normalized by first scaling the expression values provided to a sum of 10,000 per cell before calculating log2(scaled_counts+1). Averages were then performed by cluster and region for each gene. Genes associated with palmitoylation were selected in order to create the heatmaps, categories comprising fewer than 5 single cells are not displayed.

For Rosenberg, single-cell counts (UMI from 3' end counting) were downloaded from GSE110823, and log normalized by first scaling the expression values provided to a sum of 10,000 per cell before calculating log2(scaled_counts+1). Averages were then performed by brain region, neurotransmitter and taxonomy for each gene. Genes associated with palmitoylation were selected in order to create the heatmaps.

Data from Sjöstedt el al. were downloaded as Protein-coding transcripts per million (pTPM) from proteinatlas.org ("RNA mouse brain region gene data") and not further processed.

For Hipposeq, expression data were downloaded as FKPM directly from hipposeq.janelia.org and were not further processed.

For Allen Brain 10X data, expression data were downloaded as trimmed means (25%-75%) Log2(CPM+1) from portal.brain-map.org/ and were not further processed.

Correlation analysis

Spearman correlation values between genes and their significances were calculated in R using the expression results obtained for each cell type as described above.

Identification of *S*-palmitoylation substrates with SwissPalm

Gene lists were inputted into SwissPalm (https://swisspalm.org/proteins) input file function and cross-referenced with 'Dataset 3: Palmitoylation validated or found in at least one palmitoyl-proteome (SwissPalm annotated)' for *Mus musculus*, with an additional filter for UniProt 'Reviewed' proteins.

Generating a predicted palmitoylome for dorsal hippocampus

To curate the regionally enriched predicted-palmitoylome, the enrichment analysis tools in hipposeq (https://hipposeq.janelia.org/) were used to compare each of the selected Cell Lines vs the other Cell Lines in the analysis (Selected Cell Lines = dorsal DG, CA3, CA2 and CA1), with the following parameters: 'Fold threshold' = 1.5; 'FKPMmin threshold' = 5, 'FDR' = 0.05. The resulting lists of regionally enriched transcripts were cross referenced with SwissPalm as described above to identify regionally enriched *S*-palmitoylation substrates.

Bioinformatic analysis

Gene Ontology (GO) analysis was performed using statistical overrepresentation tests in PANTHER16.0 (Mi et al., 2009) with default settings and *Mus musculus* as the reference species. Biological process GO terms were extracted and ranked according to false discovery rate (FDR). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was performed using the web-based program Enrichr (Chen et al., 2013; Kuleshov et al., 2016) and ranked according to -log Adjusted P-value. Synaptic Gene Ontologies (SynGO; version 1.1) analysis was performed using default settings with brain expressed genes as a background and terms for 'biological process' were ranked according to -log Adjusted P-value. Functional protein interaction networks were identified using the Search Tool for the Retrieval of Interacting Genes (STRING) 11.0 (Szklarczyk et al., 2019) with *Mus musculus* as the reference species. Seven types of protein interactions were used for network generation, including text mining, neighborhood, co-occurrence, co-expression, gene fusion, experiments and databases.

Data presentation

Heatmaps were plotted and hierarchical clustering performed in Displayr (https://www.displayr.com) using the 'Dendrogram' function. Cytoscape (Version 3.8.0) was used to draw correlation networks.

Heatmap creation for BrainPalmSeq

All plots for the BrainPalmSeq database were generated using curated RNA sequencing datasets. Python 3 and Javascript scripts were used with the plotting library Bokeh to generate the interactive heatmaps to display and compare these datasets on the BrainPalmSeq website (Bokeh Development Team, 2018).

Cell culture

HEK293T cells were thawed and aliquoted into a 10cm dish with 10mL prewarmed (37°C) DMEM (GIBCO, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (GIBCO, Thermo Fisher Scientific, Waltham, MA) and 1% Pen/Strep(P/S) (GIBCO, Thermo Fisher Scientific, Waltham, MA). HEK293T cells were then placed in a 37°C incubator with 5% CO_2 and passaged approximately every 5 days, or once confluency was achieved.

Transfection

70%-80% confluent HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA) according to the manufacturer's recommendations. Each well of a 6-well plate was transfected with a total of 3ug DNA, 150uL of Opti-Mem (GIBCO, Thermo Fisher Scientific, Waltham, MA) was used with 6uL of Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA). Experimental condition wells were transfected with 1ug of the indicated construct of interest, 1ug of HA-DHHC9 (mouse; Shimell et al., 2019), and 1ug of FLAG-GOLGA7 (Maurine Linder, Washington University School of Medicine). Human FLAG-MOBP (CAT#: RC223946), FLAG-PLP1 (CAT#: RC218616) and FLAG-CNP (CAT#: RC207038) were acquired from Origene, Maryland, USA. Control condition wells were transfected with 1ug of the indicated construct of interest, and 2ug of a scrambled control plasmid. Cells were lysed using the acyl-RAC assay lysis buffer 48hours after transfection.

Palmitoylation Assay (acyl-RAC)

The commercially available CAPTUREome S-palmitoylated protein kit (Badrilla, Leeds, UK) was used in accordance with the manufacturer's guidelines with three optimizations: (1) prior to the cell lysis step, wells were washed with 1mL of 1X PBS to eliminate any dead cells or residual media; (2) during the cell lysis step, DNase (Sigma-Aldrich, St. Louis, MO), was added to the solution (5uL per 500uL of lysis buffer); and (2) protein concentration was measured prior to the separation of experimental sample and negative control sample using the BCA Assay (Pierce, Thermo Fisher Scientific, Waltham, MA).

Western Blot Analysis

Western blotting was performed using 4% stacking and 12% resolving SDS-PAGE gels. PVDF membranes were then blocked for 1hour at room temperature with 5% BSA in 0.05% TBS-T. PVDF membranes were incubated with the indicated primary antibodies (anti-HA: Cell Signaling Technology, C29F4, Rabbit mAb CAT#: 3724, 1:1000; anti-FLAG: Origene, mouse monoclonal antibody, CAT#: TA50011-100, 1:1000) overnight at 4°C. Proteins were then visualized using enhanced chemiluminescence (Immubilon Western Chemiluminescent HRP Substrate) on a BioRad ChemiDoc XRS+ scanner. Blots were then quantified using Fiji1 software. The palmitoylated and unpalmitoylated fractions were calculated using the following equations respectively: (Palm Fraction / (Palm Fraction + Unpalm Fraction)) and (Unpalm Fraction / (Palm Fraction + Unpalm Fraction)). Criteria for data inclusion were sufficient transfection/antibody signal and minimal protein in the non-specific binding control.

Statistical Analysis

Spearman correlations were performed with the function cor in R, and their significances were obtained using the function cor.test followed by a correction for multiple testing using p.adjust with the fdr method (Benjamini & Hochberg). For assessing enrichment of *S*-palmitoylation substrates within Zdhhc co-expressed genes, Fisher's exact test was performed using the function fisher.test in R.

For validation of substrates using Acyl-Rac palmitoylation assay, two-way ANOVA with Šídák's *post hoc* was used to assess significance of both palmitoylated and unpalmitoylated fractions. Statistics are shown for palmitoylated fraction. No outliers were excluded. Statistical analyses were performed in GraphPad Prism 9.2.0 (San Diego, CA, USA). *n* represents the number of individual HEK cell culture dishes. Each culture dish is defined as a biological replicate. No technical replicates were performed.

Acknowledgements

The authors would like to thank Drs. A. Ciernia, M. Cembrowski, T. Murphy and J. LeDue for helpful discussion. This work was supported by CIHR Foundation grant (F18-00650) to SXB and by computational resources made available through the NeuroImaging and NeuroComputation Centre at the Djavad Mowafaghian Centre for Brain Health (RRID SCR_019086) and the Dynamic Brain Circuits in Health and Disease Research Excellence Cluster DataBinge Forum.

References

Abrami L, Dallavilla T, Sandoz PA, Demir M, Kunz B, Savoglidis G, Hatzimanikatis V, van Der Goot FG.

2017. Identification and dynamics of the human ZDHHC16-ZDHHC6 palmitoylation cascade. *eLife* **6**.

doi:10.7554/eLife.27826

Baker K, Astle DE, Scerif G, Barnes J, Smith J, Moffat G, Gillard J, Baldeweg T, Raymond FL. 2015.

Epilepsy, cognitive deficits and neuroanatomy in males with ZDHHC9 mutations. *Annals of Clinical*

and Translational Neurology **2**:559–569. doi:10.1002/acn3.196

Bathelt J, Astle D, Barnes J, Raymond FL, Baker K. 2016. Structural brain abnormalities in a single gene

disorder associated with epilepsy, language impairment and intellectual disability. *NeuroImage:*

Clinical **12**:655–665. doi:10.1016/j.nicl.2016.07.016

Bathelt J, Barnes J, Raymond FL, Baker K, Astle D. 2017. Global and Local Connectivity Differences

Converge With Gene Expression in a Neurodevelopmental Disorder of Known Genetic Origin.

Cerebral Cortex **27**:3806–3817. doi:10.1093/cercor/bhx027

Bird CM, Burgess N. 2008. The hippocampus and memory: Insights from spatial processing. *Nature*

Reviews Neuroscience **9**:182–194. doi:10.1038/nrn2335

Blanc M, David F, Abrami L, Migliozzi D, Armand F, Bürgi J, van der Goot FG. 2015. SwissPalm: Protein

Palmitoylation database. *F1000Research* **4**. doi:10.12688/f1000research.6464.1

Blanc M, David FPA, van der Goot FG. 2019. SwissPalm 2: Protein S-palmitoylation databaseMethods in

Molecular Biology. Humana Press Inc. pp. 203–214. doi:10.1007/978-1-4939-9532-5_16

Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles G V., Clark NR, Ma'ayan A. 2013. Enrichr: Interactive

and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**.

doi:10.1186/1471-2105-14-128

Chen WY, Shi YY, Zheng YL, Zhao XZ, Zhang GJ, Chen SQ, Yang P Di, He L. 2004. Case-control study and

transmission disequilibrium test provide consistent evidence for association between

schizophrenia and genetic variation in the 22q11 gene ZDHHC8. *Human Molecular Genetics*

13:2991–2995. doi:10.1093/hmg/ddh322

Cho E, Park M. 2016. Palmitoylation in Alzheimer's disease and other neurodegenerative diseases.

Pharmacological Research **111**:133–151. doi:10.1016/j.phrs.2016.06.008

Forrester MT, Hess DT, Thompson JW, Hultman R, Moseley MA, Stamler JS, Casey PJ. 2011. Site-specific

analysis of protein S-acylation by resin-assisted capture. *Journal of Lipid Research* **52**:393–398.

doi:10.1194/JLR.D011106/ATTACHMENT/AA2B322B-A63D-41C0-A864-92DAC7C09076/MMC1.PDF

Fredericks G, Hoffmann F, Hondal R, Rozovsky S, Urschitz J, Hoffmann P. 2017. Selenoprotein K Increases

Efficiency of DHHC6 Catalyzed Protein Palmitoylation by Stabilizing the Acyl-DHHC6 Intermediate.

Antioxidants **7**:4. doi:10.3390/antiox7010004

Fredericks GJ, Hoffmann FKW, Rose AH, Osterheld HJ, Hess FM, Mercier F, Hoffmann PR. 2014. Stable

expression and function of the inositol 1,4,5-triphosphate receptor requires palmitoylation by a

DHHC6/selenoprotein K complex. *Proceedings of the National Academy of Sciences of the United*

States of America **111**:16478–16483. doi:10.1073/pnas.1417176111

Fukata Y, Dimitrov A, Boncompain G, Vielemeyer O, Perez F, Fukata M. 2013. Local palmitoylation cycles

define activity-regulated postsynaptic subdomains. *Journal of Cell Biology* **202**:145–161.

doi:10.1083/jcb.201302071

Fukata Y, Fukata M. 2010. Protein palmitoylation in neuronal development and synaptic plasticity.

Nature Reviews Neuroscience **11**:161–175. doi:10.1038/nrn2788

Glantz LA, Lewis DA. 2000. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in

schizophrenia. *Archives of General Psychiatry* **57**:65–73. doi:10.1001/archpsyc.57.1.65

Globa AK, Bamji SX. 2017. Protein palmitoylation in the development and plasticity of neuronal

connections. *Current Opinion in Neurobiology* **45**:210–220. doi:10.1016/j.conb.2017.02.016

Gorinski N, Bijata M, Prasad S, Wirth A, Abdel Galil D, Zeug A, Bazovkina D, Kondaurova E, Kulikova E,

Ilchibaeva T, Zareba-Koziol M, Papaleo F, Scheggia D, Kochlamazashvili G, Dityatev A, Smyth I,

Krzystyniak A, Wlodarczyk J, Richter DW, Strekalova T, Sigrist S, Bang C, Hobuß L, Fiedler J, Thum T,

Naumenko VS, Pandey G, Ponimaskin E. 2019. Attenuated palmitoylation of serotonin receptor 5-

HT1A affects receptor function and contributes to depression-like behaviors. *Nature*

Communications **10**:1–14. doi:10.1038/s41467-019-11876-5

Haque A, Engel J, Teichmann SA, Lönnberg T. 2017. A practical guide to single-cell RNA-sequencing for

biomedical research and clinical applications. *Genome Medicine* **9**:1–12. doi:10.1186/s13073-017-

0467-4

Harris KD, Shepherd GMG. 2015. The neocortical circuit: Themes and variations. *Nature Neuroscience*
18:170–181. doi:10.1038/nn.3917

Ji B, Skup M. 2021. Roles of palmitoylation in structural long-term synaptic plasticity. *Molecular Brain*
14:1–27. doi:10.1186/s13041-020-00717-y

Kang R, Wan J, Arstikaitis P, Takahashi H, Huang K, Bailey AO, Thompson JX, Roth AF, Drisdel RC, Mastro
R, Green WN, Yates JR, Davis NG, El-Husseini A. 2008. Neural palmitoyl-proteomics reveals dynamic
synaptic palmitoylation. *Nature* **456**:904–909. doi:10.1038/nature07605

Karayiorgou M, Simon TJ, Gogos JA. 2010. 22q11.2 microdeletions: Linking DNA structural variation to
brain dysfunction and schizophrenia. *Nature Reviews Neuroscience* **11**:402–416.
doi:10.1038/nrn2841

Kolluri N, Sun Z, Sampson AR, Lewis DA. 2005. Lamina-specific reductions in dendritic spine density in
the prefrontal cortex of subjects with schizophrenia. *American Journal of Psychiatry* **162**:1200–
1202. doi:10.1176/appi.ajp.162.6.1200

Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP, Cornelisse LN, Farrell RJ,
Goldschmidt HL, Howrigan DP, Hussain NK, Imig C, de Jong APH, Jung H, Kohansalnodehi M,
Kramarz B, Lipstein N, Lovering RC, MacGillavry H, Mariano V, Mi H, Ninov M, Osumi-Sutherland D,
Pielot R, Smalla KH, Tang H, Tashman K, Toonen RFG, Verpelli C, Reig-Viader R, Watanabe K, van
Weering J, Achsel T, Ashrafi G, Asi N, Brown TC, De Camilli P, Feuermann M, Foulger RE, Gaudet P,
Joglekar A, Kanellopoulos A, Malenka R, Nicoll RA, Pulido C, de Juan-Sanz J, Sheng M, Südhof TC,
Tilgner HU, Bagni C, Bayés À, Biederer T, Brose N, Chua JJE, Dieterich DC, Gundelfinger ED,
Hoogenraad C, Huganir RL, Jahn R, Kaeser PS, Kim E, Kreutz MR, McPherson PS, Neale BM,
O'Connor V, Posthuma D, Ryan TA, Sala C, Feng G, Hyman SE, Thomas PD, Smit AB, Verhage M.
2019. SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. *Neuron*
103:217-234.e4. doi:10.1016/j.neuron.2019.05.002

Koster KP, Yoshii A. 2019. Depalmitoylation by palmitoyl-protein thioesterase 1 in neuronal health and
degeneration. *Frontiers in Synaptic Neuroscience* **11**:25. doi:10.3389/fnsyn.2019.00025

Kouskou M, Thomson DM, Brett RR, Wheeler L, Tate RJ, Pratt JA, Chamberlain LH. 2018. Disruption of
the Zdhhc9 intellectual disability gene leads to behavioural abnormalities in a mouse model.
Experimental Neurology **308**:35–46. doi:10.1016/J.EXPNEUROL.2018.06.014

Kuleshov M V., Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik
KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. 2016. Enrichr: a
comprehensive gene set enrichment analysis web server 2016 update. *Nucleic acids research*
44:W90–W97. doi:10.1093/nar/gkw377

Lemonidis K, Sanchez-Perez MC, Chamberlain LH. 2015. Identification of a novel sequence motif
recognized by the ankyrin repeat domain of zDHHC17/13 S-acyltransferases. *Journal of Biological*
Chemistry **290**:21939–21950. doi:10.1074/jbc.M115.657668

Lin DTS, Conibear E. 2015. ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras
palmitate turnover and subcellular localization. *eLife* **4**. doi:10.7554/eLife.11306

Lu JY, Verkruyse LA, Hofmann SL. 1996. Lipid thioesters derived from acylated proteins accumulate in
infantile neuronal ceroid lipofuscinosis: Correction of the defect in lymphoblasts by recombinant
palmitoyl-protein thioesterase. *Proceedings of the National Academy of Sciences of the United*
States of America **93**:10046–10050. doi:10.1073/pnas.93.19.10046

Ma Y, Liu H, Ou Z, Qi C, Xing R, Wang S, Han Y, Zhao T-J, Chen Y. 2021. DHHC5 facilitates oligodendrocyte
development by palmitoylating and activating STAT3. *Glia*. doi:10.1002/glia.24113

Malgapo MIP, Linder ME. 2021. Substrate recruitment by zDHHC protein acyltransferases. *Open Biology*
11:rsob.210026. doi:10.1098/rsob.210026

Marques S, Zeisel A, Codeluppi S, Van Bruggen D, Falcão AM, Xiao L, Li H, Häring M, Hochgerner H,
Romanov RA, Gyllborg D, Muñoz-Manchado AB, La Manno G, Lönnerberg P, Floriddia EM, Rezayee
F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G.
2016. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system.
Science **352**:1326–1329. doi:10.1126/science.aaf6463

Matt L, Kim K, Chowdhury D, Hell JW. 2019. Role of palmitoylation of postsynaptic proteins in promoting
synaptic plasticity. *Frontiers in Molecular Neuroscience*. doi:10.3389/fnmol.2019.00008

Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. 2009. PANTHER version 7: Improved
phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. *Nucleic Acids*
Research **38**. doi:10.1093/nar/gkp1019

Mitchell DA, Hamel LD, Reddy KD, Farh L, Rettew LM, Sanchez PR, Deschenes RJ. 2014. Mutations in the

X-linked intellectual disability gene, zDHHC9, alter autopalmitoylation activity by distinct

mechanisms. *Journal of Biological Chemistry* **289**:18582–18592. doi:10.1074/jbc.M114.567420

Mukai J, Liu H, Burt RA, Swor DE, Lai WS, Karayiorgou M, Gogos JA. 2004. Evidence that the gene

encoding ZDHHC8 contributes to the risk of schizophrenia. *Nature Genetics* **36**:725–731.

doi:10.1038/ng1375

Nita DA, Mole SE, Minassian BA. 2016. Neuronal ceroid lipofuscinoses. *Epileptic Disorders* **18**:S73–S88.

doi:10.1684/epd.2016.0844

Pitts MW, Hoffmann PR. 2018. Endoplasmic reticulum-resident selenoproteins as regulators of calcium

signaling and homeostasis. *Cell Calcium* **70**:76–86. doi:10.1016/j.ceca.2017.05.001

Plain F, Howie J, Kennedy J, Brown E, Shattock MJ, Fraser NJ, Fuller W. 2020. Control of protein

palmitoylation by regulating substrate recruitment to a zDHHC-protein acyltransferase.

Communications Biology **3**:1–10. doi:10.1038/s42003-020-01145-3

Rana MS, Lee CJ, Banerjee A. 2018. The molecular mechanism of DHHC protein acyltransferases.

Biochemical Society Transactions **47**:157–167. doi:10.1042/BST20180429

Raymond FL, Tarpey PS, Edkins S, Tofts C, O'Meara S, Teague J, Butler A, Stevens C, Barthorpe S, Buck G,

Cole J, Dicks E, Gray K, Halliday K, Hills K, Hinton J, Jones D, Menzies A, Perry J, Raine K, Shepherd R,

Small A, Varian J, Widaa S, Mallya U, Moon J, Luo Y, Shaw M, Boyle J, Kerr B, Turner G, Quarrell O,

Cole T, Easton DF, Wooster R, Bobrow M, Schwartz CE, Gecz J, Stratton MR, Futreal PA. 2007.

Mutations in ZDHHC9, Which Encodes a Palmitoyltransferase of NRAS and HRAS, Cause X-Linked

Mental Retardation Associated with a Marfanoid Habitus. *The American Journal of Human Genetics*

80:982–987. doi:10.1086/513609

Roberts MS, Macauley SL, Wong AM, Yilmas D, Hohm S, Cooper JD, Sands MS. 2012. Combination small

molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid

lipofuscinosis. *Journal of Inherited Metabolic Disease* **35**:847–857. doi:10.1007/s10545-011-9446-x

Rocks O, Gerauer M, Vartak N, Koch S, Huang ZP, Pechlivanis M, Kuhlmann J, Brunsveld L, Chandra A,

Ellinger B, Waldmann H, Bastiaens PIH. 2010. The palmitoylation machinery is a spatially organizing

system for peripheral membrane proteins. *Cell* **141**:458–471. doi:10.1016/j.cell.2010.04.007

Rodenburg RNP, Snijder J, Van De Waterbeemd M, Schouten A, Granneman J, Heck AJR, Gros P. 2017.

Stochastic palmitoylation of accessible cysteines in membrane proteins revealed by native mass
spectrometry. *Nature Communications* **8**:1–9. doi:10.1038/s41467-017-01461-z

Rosenberg AB, Roco CM, Muscat RA, Kuchina A, Sample P, Yao Z, Graybuck LT, Peeler DJ, Mukherjee S,
Chen W, Pun SH, Sellers DL, Tasic B, Seelig G. 2018. Single-cell profiling of the developing mouse
brain and spinal cord with split-pool barcoding. *Science* **360**:176–182.
doi:10.1126/science.aam8999

Salaun C, Locatelli C, Zmuda F, González JC, Chamberlain LH. 2020. Accessory proteins of the zDHHC
family of S-acylation enzymes. *Journal of Cell Science* **133**. doi:10.1242/jcs.251819

Sanders SS, Martin DDO, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, Yates JR, Hayden MR. 2015.
Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases
and Disorders of the Nervous System and Cancers. *PLoS Computational Biology* **11**:e1004405.
doi:10.1371/journal.pcbi.1004405

Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L,
Wang S, Goeva A, Nemesh J, Kamitaki N, Brumbaugh S, Kulp D, McCarroll SA. 2018. Molecular
Diversity and Specializations among the Cells of the Adult Mouse Brain. *Cell* **174**:1015-1030.e16.
doi:10.1016/j.cell.2018.07.028

Schneider A, Länder H, Schulz G, Wolburg H, Nave K-A, Schulz JB, Simons M. 2005. Palmitoylation is a
sorting determinant for transport to the myelin membrane. *Journal of cell science* **118**:2415–23.
doi:10.1242/jcs.02365

Schwarz F, Aebi M. 2011. Mechanisms and principles of N-linked protein glycosylation. *Current Opinion*
in Structural Biology **21**:576–582. doi:10.1016/j.sbi.2011.08.005

Shimell JJ, Shah BS, Cain SM, Thouta S, Kuhlmann N, Tatarnikov I, Jovellar DB, Brigidi GS, Kass J,
Milnerwood AJ, Snutch TP, Bamji SX. 2019. The X-Linked Intellectual Disability Gene Zdhhc9 Is
Essential for Dendrite Outgrowth and Inhibitory Synapse Formation. *Cell Reports* **29**:2422-2437.e8.
doi:10.1016/j.celrep.2019.10.065

Shyng C, Nelvagal HR, Dearborn JT, Tyynelä J, Schmidt RE, Sands MS, Cooper JD. 2017. Synergistic effects
of treating the spinal cord and brain in CLN1 disease. *Proceedings of the National Academy of*
Sciences of the United States of America **114**:E5920–E5929. doi:10.1073/pnas.1701832114

Sjöstedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, Oksvold P, Edfors F, Limiszewska A,

Hikmet F, Huang J, Du Y, Lin L, Dong Z, Yang L, Liu X, Jiang H, Xu X, Wang J, Yang H, Bolund L,

Mardinoglu A, Zhang C, von Feilitzen K, Lindskog C, Pontén F, Luo Y, Hökfelt T, Uhlén M, Mulder J.

2020. An atlas of the protein-coding genes in the human, pig, and mouse brain. *Science*

367:eaay5947. doi:10.1126/science.aay5947

Solis GP, Valnohova J, Alvarez C, Katanaev VL. 2020. Local and substrate-specific S-palmitoylation

determines subcellular localization of Gαo. *bioRxiv* 2020.08.25.266692.

doi:10.1101/2020.08.25.266692

Swarthout JT, Lobo S, Farh L, Croke MR, Greentree WK, Deschenes RJ, Linder ME. 2005. DHHC9 and

GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras. *Journal of*

Biological Chemistry **280**:31141–31148. doi:10.1074/jbc.M504113200

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH,

Bork P, Jensen LJ, Von Mering C. 2019. STRING v11: Protein-protein association networks with

increased coverage, supporting functional discovery in genome-wide experimental datasets.

Nucleic Acids Research **47**:D607–D613. doi:10.1093/nar/gky1131

Tasic B, Yao Z, Graybuck LT, Smith KA, Nguyen TN, Bertagnolli D, Goldy J, Garren E, Economo MN,

Viswanathan S, Penn O, Bakken T, Menon V, Miller J, Fong O, Hirokawa KE, Lathia K, Rimorin C,

Tieu M, Larsen R, Casper T, Barkan E, Kroll M, Parry S, Shapovalova N V., Hirschstein D, Pendergraft

J, Sullivan HA, Kim TK, Szafer A, Dee N, Groblewski P, Wickersham I, Cetin A, Harris JA, Levi BP,

Sunkin SM, Madisen L, Daigle TL, Looger L, Bernard A, Phillips J, Lein E, Hawrylycz M, Svoboda K,

Jones AR, Koch C, Zeng H. 2018. Shared and distinct transcriptomic cell types across neocortical

areas. *Nature* **563**:72–78. doi:10.1038/s41586-018-0654-5

Thomas GM, Hayashi T, Chiu SL, Chen CM, Huganir RL. 2012. Palmitoylation by DHHC5/8 Targets GRIP1

to Dendritic Endosomes to Regulate AMPA-R Trafficking. *Neuron* **73**:482–496.

doi:10.1016/j.neuron.2011.11.021

Thomas GM, Hayashi T, Huganir RL, Linden DJ. 2013. DHHC8-dependent PICK1 palmitoylation is required

for induction of cerebellar long-term synaptic depression. *Journal of Neuroscience* **33**:15401–

15407. doi:10.1523/JNEUROSCI.1283-13.2013

Tzschach A, Grasshoff U, Beck-Woedl S, Dufke C, Bauer C, Kehrer M, Evers C, Moog U, Oehl-Jaschkowitz

B, Donato N Di, Maiwald R, Jung C, Kuechler A, Schulz S, Meinecke P, Spranger S, Kohlhase J, Seidel

J, Reif S, Rieger M, Riess A, Sturm M, Bickmann J, Schroeder C, Dufke A, Riess O, Bauer P. 2015.

Next-generation sequencing in X-linked intellectual disability. *European Journal of Human Genetics*

23:1513–1518. doi:10.1038/ejhg.2015.5

Ubersax JA, Ferrell JE. 2007. Mechanisms of specificity in protein phosphorylation. *Nature Reviews*

Molecular Cell Biology **8**:530–541. doi:10.1038/nrm2203

Vartak N, Papke B, Grecco HE, Rossmannek L, Waldmann H, Hedberg C, Bastiaens PIH. 2014. The

autodepalmitoylating activity of APT maintains the spatial organization of palmitoylated

membrane proteins. *Biophysical Journal* **106**:93–105. doi:10.1016/j.bpj.2013.11.024

Verardi R, Kim JS, Ghirlando R, Banerjee A. 2017. Structural Basis for Substrate Recognition by the

Ankyrin Repeat Domain of Human DHHC17 Palmitoyltransferase. *Structure* **25**:1337-1347.e6.

doi:10.1016/j.str.2017.06.018

Virlogeux A, Scaramuzzino C, Lenoir S, Carpentier R, Louessard M, Genoux A, Lino P, Hinckelmann MV,

Perrier AL, Humbert S, Saudou F. 2021. Increasing brain palmitoylation rescues behavior and

neuropathology in Huntington disease mice. *Science Advances* **7**:799–830.

doi:10.1126/sciadv.abb0799

Wagstyl K, Ronan L, Whitaker KJ, Goodyer IM, Roberts N, Crow TJ, Fletcher PC. 2016. Multiple markers

of cortical morphology reveal evidence of supragranular thinning in schizophrenia. *Translational*

Psychiatry **6**:780. doi:10.1038/tp.2016.43

Woodley KT, Collins MO. 2019. S-acylated Golga7b stabilises <scp>DHHC</scp> 5 at the plasma

membrane to regulate cell adhesion. *EMBO reports* **20**:e47472. doi:10.15252/embr.201847472

Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, Orban PC, Mullard A, Cowan CM, Raymond

LA, Drisdel RC, Green WN, Ravikumar B, Rubinsztein DC, El-Husseini A, Hayden MR. 2006.

Palmitoylation of huntingtin by HIP14is essential for its trafficking and function. *Nature*

Neuroscience **9**:824–831. doi:10.1038/nn1702

Yao Z, van Velthoven CTJ, Nguyen TN, Goldy J, Sedeno-Cortes AE, Baftizadeh F, Bertagnolli D, Casper T,

Chiang M, Crichton K, Ding SL, Fong O, Garren E, Glandon A, Gouwens NW, Gray J, Graybuck LT,

Hawrylycz MJ, Hirschstein D, Kroll M, Lathia K, Lee C, Levi B, McMillen D, Mok S, Pham T, Ren Q,

Rimorin C, Shapovalova N, Sulc J, Sunkin SM, Tieu M, Torkelson A, Tung H, Ward K, Dee N, Smith

KA, Tasic B, Zeng H. 2021. A taxonomy of transcriptomic cell types across the isocortex and

hippocampal formation. *Cell* **184**:3222-3241.e26. doi:10.1016/j.cell.2021.04.021

Yuan W, Lu L, Rao M, Huang Y, Liu CE, Liu S, Zhao Y, Liu H, Zhu J, Chao T, Wu C, Ren J, Lv L, Li W, Qi S,

Liang Y, Yue S, Gao J, Zhang Z, Kong E. 2021. GFAP hyperpalmitoylation exacerbates astrogliosis and

neurodegenerative pathology in PPT1-deficient mice. *Proceedings of the National Academy of*

Sciences of the United States of America **118**. doi:10.1073/pnas.2022261118

Zareba-Koziol M, Bartkowiak-Kaczmarek A, Figiel I, Krzystyniak A, Wojtowicz T, Bijata M, Wlodarczyk J.

2019. Stress-induced Changes in the S-palmitoylation and S-nitrosylation of Synaptic Proteins.

Molecular and Cellular Proteomics **18**:1916–1938. doi:10.1074/mcp.RA119.001581

Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, Häring M, Braun E, Borm LE,

La Manno G, Codeluppi S, Furlan A, Lee K, Skene N, Harris KD, Hjerling-Leffler J, Arenas E, Ernfors P,

Marklund U, Linnarsson S. 2018. Molecular Architecture of the Mouse Nervous System. *Cell*

174:999-1014.e22. doi:10.1016/j.cell.2018.06.021

Zeisel A, Moz-Manchado AB, Codeluppi S, Lönnerberg P, Manno G La, Juréus A, Marques S, Munguba H,

He L, Betsholtz C, Rolny C, Castelo-Branco G, Hjerling-Leffler J, Linnarsson S. 2015. Cell types in the

mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* **347**:1138–1142.

doi:10.1126/science.aaa1934

Figure1

Figure 2

Figure 3

Figure 4

Figure 5

A. *Zdhhc8* neonatal expression
Rosenberg et al <P11

Cortex/HC neuron
Midbrain/hindbrain neuron
Olfactory neuron
Migrating interneuron
Oligodendrocyte
Cerebellum neuron
Microglia
Spinal cord neuron
OPC
Vascular
Astrocyte
Ependymal
Macrophage

0.14
0.07
0.0
expression

B. *Zdhhc8* adolescent expression
'MouseBrain' P25

Cortex/HC neuron
Midbrain/hindbrain neuron
Interneuron
Spinal cord neuron
Oligodendrocyte
Vascular
Cerebellum neuron
Olfactory neuron
OPC
Astrocytes
Ependymal
Microglia
Macrophage

0.5
0.25
0.0
expression

C. *Zdhhc8* adult expression
'Protein Atlas' Mouse P60

0 5 10 15
expression

D. *Zdhhc9* neonatal expression
Rosenberg et al <P11

Oligodendrocyte
Midbrain/hindbrain neuron
Cortex/HC neuron
Olfactory neuron
Spinal cord neuron
Macrophage
Migrating interneuron
Cerebellum neuron
Vascular
Microglia
OPC
Ependymal
Astrocyte

0.28
0.14
0.0
expression

E. *Zdhhc9* adolescent expression
'MouseBrain' P25

Oligodendrocyte
Cortex/HC neuron
Midbrain/hindbrain neuron
Vascular
Interneuron
Spinal cord neuron
Ependymal
OPC
Cerebellum neuron
Macrophage
Olfactory neuron
Astrocytes
Microglia

1.0
0.5
0.0
expression

F. *Zdhhc9* adult expression
'Protein Atlas' Mouse P60

0 20 40 60 80 100
expression

G. *Ppt1* neonatal expression
Rosenberg et al <P11

Olfactory neuron
Spinal cord neuron
Microglia
Midbrain/hindbrain neuron
Cortex/HC neuron
Migrating interneuron
Cerebellum neuron
Astrocyte
OPC
Oligodendrocyte
Ependymal
Vascular
Macrophage

1.5
0.75
0.0
expression

H. *Ppt1* adolescent expression
'MouseBrain' P25

Microglia
Interneuron
Midbrain/hindbrain neuron
Macrophage
Cortex/HC neuron
Spinal cord neuron
OPC
Oligodendrocyte
Astrocytes
Ependymal
Olfactory neuron
Vascular
Cerebellum neuron

0.6
0.3
0.0
expression

I. *Ppt1* adult expression
'Protein Atlas' Mouse P60

0 40 80 120
expression

Figure 6